Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
about
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreating childhood acute lymphoblastic leukemia without cranial irradiationA subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyHaploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesRecent advancements of bortezomib in acute lymphocytic leukemia treatmentPrognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.Childhood acute lymphoblastic leukemia: Integrating genomics into therapyAssociation of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemiaAntileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell LinesExperience of pandemic influenza with H1N1 in children with leukemia.Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.High-risk childhood acute lymphoblastic leukemiaThe Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic LeukemiaPrognostic factors and treatment of pediatric acute lymphoblastic leukemia.Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology.Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships.Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis.Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginasePediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Improved prognosis for older adolescents with acute lymphoblastic leukemia.Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's OnOutcomes of dose-adjusted Berlin-Frankfurt-Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma.Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcomeSubgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase HypersensitivityPrediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survivalKRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
P2860
Q24193790-D289BB23-1DA9-4249-B325-31E299885E51Q24234833-660FC5D7-9E26-4D48-90C8-69C8031FDAF0Q24644599-1F4E91D2-560B-4C0E-B4F6-99AE45BB7912Q24651897-CBA89A8C-C0AA-4AB9-B18D-198C3AC79B36Q26750671-86840B4C-7803-4DC3-B78E-41A2DB824CCEQ26829613-C280F31F-8D8D-4F5A-94C4-D3FE8491CCE5Q27851831-084C18E2-4BD3-4E99-AF3F-FE94B6FE4EDEQ28080463-B547231B-5C8C-4C7E-A86A-613B47449A2AQ28538292-F6ECBCBD-47DA-4B82-B74B-EBBEACCCE357Q28553697-AFC00E79-08CF-4DA1-A09F-239DC148F846Q30396331-D014090A-3C7E-40D9-B951-C999AED8A315Q33395001-2D8062D5-D746-48E4-A5A6-C79B4E0D56DAQ33398162-F9A14973-21CA-4142-9632-0B352A41FD52Q33587619-5062AFD4-E358-452D-9119-096A1BD65641Q33590468-458E2215-19AB-42A7-BE32-DB965A0B3310Q33622837-6807A85F-7CF4-4D6A-8C5F-A869E05F1812Q33636082-F9D3E5CB-CB15-493F-B57B-CF342282692FQ33736847-8BF8FC8C-DB4A-48AD-86A4-D03F2BA1277EQ33770150-67BA7A29-CBD2-4A14-B65F-5B7CC12398D9Q33828575-C1A66F82-77ED-4CAD-A91D-B64EADCE886BQ33888105-1B9D2904-3F00-4171-AF04-1555517C6A37Q33931882-7F6BFA15-7D43-452D-B053-7036BA9F65E8Q34016431-628597D1-4A65-440D-AF28-A7411919003FQ34079996-2E60BCB2-7A7C-4390-B42F-6E0A14FF9094Q34240618-8374925A-37D0-4A56-9361-E41667379496Q34278721-607BB720-E389-478B-A9C5-8AC41B743FB4Q34371730-748A3208-9839-41AE-A58F-4DC59632329DQ34400424-85B858C6-9CCE-4B12-9E13-FCB8235D80EEQ34490429-EEEBF4E6-41AC-4BEB-AC64-D7EF4B14DC08Q34645259-7C93B888-46F4-44E2-ABA9-6385B33CEB16Q34679298-5911E266-1AF2-4F14-A26B-F27A7893F74AQ35039727-81E29E0F-C9DD-4AB2-8C58-D2ABF665C827Q35159889-C4BA8FF0-454A-4F3B-A325-8B7B09A0DF33Q35437903-8F2EB377-3410-4C86-A12F-56ED5BC7B37EQ35458883-8660DC7B-069A-4E36-8B22-01415F9F2991Q35794444-12CCAD1C-B6BB-4864-91FD-76FC4FBC678FQ35803355-787F4744-D90F-46AA-B8C2-414C7965651EQ35853569-B2780C29-4B13-4189-9544-1B6AC5C8088BQ35901969-ED816A0A-FECF-4928-9BAE-32C9D52CC061Q35932148-CA5FE26C-5A5F-413E-8E52-5182A7D856A6
P2860
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@en
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@nl
type
label
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@en
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@nl
prefLabel
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@en
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@nl
P2093
P50
P921
P1433
P1476
Risk-adjusted therapy of acute ...... olled in the trial ALL-BFM 95.
@en
P2093
Alfred Reiter
Andreas Feldges
Anja Möricke
Charlotte Niemeyer
Christian Urban
Dietrich Niethammer
Felix Zintl
Georg Mann
German-Austrian-Swiss ALL-BFM Study Group
Günter Henze
P304
P356
10.1182/BLOOD-2007-09-112920
P407
P577
2008-02-19T00:00:00Z